International Stem Cell Corporation (ISCO) stock price, revenue, and financials

International Stem Cell Corporation market cap is $10 m, and annual revenue was $11.09 m in FY 2018

$10 M

ISCO Mkt cap, 08-Oct-2018

$2.3 M

International Stem Cell Corporation Revenue Q2, 2019
International Stem Cell Corporation Gross profit (Q2, 2019)1.5 M
International Stem Cell Corporation Gross profit margin (Q2, 2019), %63.1%
International Stem Cell Corporation Net income (Q2, 2019)-648 K
International Stem Cell Corporation EBIT (Q2, 2019)-941 K
International Stem Cell Corporation Cash, 30-Jun-2019595 K

International Stem Cell Corporation Revenue

International Stem Cell Corporation revenue was $11.09 m in FY, 2018

Embed Graph

International Stem Cell Corporation Revenue Breakdown

Embed Graph

International Stem Cell Corporation revenue breakdown by business segment: 30.3% from Cosmetic and 69.7% from Biomedical

International Stem Cell Corporation revenue breakdown by geographic segment: 85.1% from North America, 9.8% from Asia and 5.1% from Other

International Stem Cell Corporation Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

6.1m7.0m7.6b7.2m7.5m11.1m

Revenue growth, %

14%107510%(100%)4%

Cost of goods sold

1.6m1.9m2.1b1.9m2.1m4.1m

Gross profit

4.5m5.1m5.5b5.2m5.3m7.0m

Gross profit Margin, %

73%73%73%73%72%63%

Sales and marketing expense

2.5m2.4m2.6m

R&D expense

3.6m5.4m2.7b2.9m2.7m2.4m

General and administrative expense

6.0m5.6m4.7b4.7m5.2m5.5m

Operating expense total

9.6m11.0m7.4b10.1m10.3m14.6m

EBIT

(4.9m)(4.9m)(3.5m)

EBIT margin, %

(68%)(66%)(31%)

Interest expense

3.0k2.0k11.0m6.0k59.0k48.0k

Pre tax profit

(10.5m)(12.5m)(2.6b)(1.1m)(6.1m)(2.1m)

Income tax expense

Net Income

(10.5m)(12.5m)(2.6m)(1.1m)(6.1m)(2.1m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

1.7m1.6m1.6m2.0m1.6m1.8b2.1b1.6b1.9b1.9b2.0b1.8m1.8b2.6m5.7m3.2m2.2m2.3m

Cost of goods sold

447.0k439.0k409.0k518.0k418.0k516.0m565.0m377.0m506.0m606.0m553.0m471.0k474.0m825.0k1.9m1.3m841.0k857.0k

Gross profit

1.2m1.2m1.2m1.4m1.2m1.3b1.6b1.2b1.4b1.3b1.5b1.3m1.4b1.8m3.8m1.9m1.4m1.5m

Gross profit Margin, %

73%73%74%74%74%72%74%77%74%69%72%73%74%69%66%59%62%63%

Sales and marketing expense

632.0k669.0k557.0k708.0k1.3m608.0k692.0k739.0k

R&D expense

932.0k958.0k1.4m1.4m1.1m567.0m508.0m579.0m852.0m679.0m645.0m739.0k670.0m811.0k1.3m616.0k653.0k268.0k

General and administrative expense

1.4m1.6m1.3m1.3m1.4m1.1b973.0m1.2b1.2b1.3b1.3b997.0k1.0b1.5m2.7m1.3m1.5m1.4m

Operating expense total

2.9m3.7m2.7m2.7m2.5m1.6b1.5b1.8b2.0b2.0b1.9b2.8m2.8b3.8m7.2m3.9m3.7m3.3m

Depreciation and amortization

248.0k

EBIT

(1.0b)(970.0m)(1.2m)(1.6m)(663.0k)(1.5m)(941.0k)

EBIT margin, %

(52%)(53%)(45%)(27%)(21%)(67%)(41%)

Interest expense

1.0k1.0k1.0k2.0m4.0m5.0m1.0m4.0m6.0m14.0k20.0m2.0k9.0k17.0k14.0k20.0k

Pre tax profit

(3.8m)(1.4m)(4.4m)(2.0m)(1.3m)723.0m(539.0m)(14.6b)10.9b414.0m(3.1b)568.0k(2.2b)(830.0k)(1.2m)121.0k(906.0k)

Income tax expense

Net Income

(3.8m)(1.4m)(4.4m)(2.0m)(1.3m)723.0m(539.0m)(14.6b)10.9b414.0m(3.1b)568.0k(2.2b)(830.0k)(1.2m)121.0k(906.0k)(648.0k)

International Stem Cell Corporation Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

2.2m1.1m532.0k110.0k304.0k1.1m

Accounts Receivable

306.0k574.0k465.0k

Prepaid Expenses

418.0k779.0k

Inventories

658.0k485.0k572.0k1.4m1.3m1.5m

Current Assets

4.6m3.6m3.0m2.5m2.9m3.8m

PP&E

830.0k714.0k375.0k396.0k321.0k469.0k

Total Assets

7.7m7.2m7.1m7.0m6.9m7.8m

Accounts Payable

532.0k670.0k1.1m841.0k830.0k458.0k

Current Liabilities

7.0m6.9m5.5m3.6m4.8m5.1m

Total Liabilities

5.3m

Common Stock

151.0k239.0k3.0k4.0k6.0k

Additional Paid-in Capital

77.9m94.8m99.0m101.9m106.6m109.2m

Retained Earnings

(82.3m)(94.7m)(97.4m)(98.5m)(104.5m)(106.7m)

Total Equity

(4.2m)321.0k1.6m3.4m2.1m2.5m

Financial Leverage

-1.8 x22.4 x4.5 x2 x3.3 x3.1 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

1.8m991.0k748.0k471.0k611.0k554.0k599.0k1.5m768.0k733.0k676.0k297.0k510.0k447.0k477.0k1.2m615.0k595.0k

Accounts Receivable

(110.0k)976.0k

Inventories

1.4m1.4m1.5m1.5m1.7m1.8m1.9m1.4m1.4m1.3m1.4m1.4m1.4m1.4m1.7m1.5m1.5m1.3m

Current Assets

4.0m3.5m3.2m2.9m3.1m3.3m3.6m4.1m3.3m3.1m3.3m2.8m3.1m3.4m4.3m4.7m3.5m3.3m

PP&E

851.0k742.0k847.0k781.0k630.0k546.0k459.0k379.0k431.0k412.0k355.0k358.0k339.0k336.0k384.0k347.0k652.0k697.0k

Total Assets

6.9m6.7m6.6m6.4m6.7m6.9m7.2m8.4m7.9m7.5m7.9m7.6m8.0m7.5m8.4m8.7m8.7m8.5m

Accounts Payable

522.0k518.0k798.0k715.0k1.8m580.0k526.0k602.0k743.0k796.0k725.0k391.0k848.0k1.6m1.8m799.0k806.0k731.0k

Current Liabilities

6.4m6.0m2.0m2.3m6.8m6.1m6.4m21.2m8.8m7.1m7.2m6.0m8.1m5.8m6.8m5.9m4.5m4.5m

Total Liabilities

5.5m5.4m

Common Stock

262.0k2.0k2.0k3.0k3.0k4.0k4.0k4.0k4.0k6.0k6.0k7.0k

Additional Paid-in Capital

75.0m79.2m87.5m89.1m95.7m96.1m96.7m99.1m100.0m101.0m102.2m102.6m102.9m107.0m107.4m108.4m110.7m102.5m

Retained Earnings

(83.7m)(88.1m)(90.1m)(96.0m)(95.3m)(95.9m)(112.0m)(101.0m)(100.6m)(101.5m)(101.0m)(103.1m)(105.4m)(105.8m)(105.6m)(107.6m)(103.7m)

Total Equity

(4.4m)(4.3m)(365.0k)(846.0k)(79.0k)805.0k834.0k(12.9m)(982.0k)425.0k638.0k1.6m(186.0k)1.6m1.6m2.8m3.2m(1.2m)

Financial Leverage

-1.6 x-1.5 x-18.1 x-7.5 x-84.7 x8.6 x8.7 x-0.7 x-8 x17.7 x12.3 x4.8 x-42.8 x4.6 x5.1 x3.1 x2.7 x-7.2 x

International Stem Cell Corporation Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(10.5m)(12.5m)(2.6m)(1.1m)6.1m(2.1m)

Depreciation and Amortization

464.0k458.0k472.0k331.0k326.0k308.0k

Accounts Receivable

(55.0k)(147.0k)(86.0k)(27.0k)109.0k(186.0k)

Inventories

(260.0k)(215.0k)(217.0k)(157.0k)(129.0k)

Accounts Payable

(437.0k)138.0k422.0k(251.0k)(11.0k)

Cash From Operating Activities

(5.6m)(6.4m)(4.1m)(4.2m)(2.1m)(1.1m)

Purchases of PP&E

(167.0k)(290.0k)(35.0k)(231.0k)(112.0k)(185.0k)

Cash From Investing Activities

(896.0k)(987.0k)(738.0k)(943.0k)(864.0k)(661.0k)

Cash From Financing Activities

8.1m6.3m4.3m4.7m3.2m2.5m

Net Change in Cash

(422.0k)194.0k

Interest Paid

3.0k2.0k2.0k14.0k1.0k3.0k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(7.7m)(1.4m)(4.4m)(2.0m)(1.3m)723.0m(539.0m)(14.6b)10.9b414.0m(3.1b)(2.5m)(4.7m)(830.0k)(1.2m)(1.1m)(906.0k)(1.6m)

Depreciation and Amortization

347.0k116.0k165.0k248.0k68.0k140.0k215.0k72.0k138.0k

Accounts Receivable

(148.0k)(195.0k)(31.0k)(110.0k)(474.0k)(1.1m)(1.1m)(306.0k)(325.0k)

Inventories

(201.0k)8.0k(33.0k)(84.0k)51.0k184.0k

Accounts Payable

(447.0k)(14.0k)798.0k715.0k1.8m580.0k526.0k602.0k743.0k796.0k725.0k(450.0k)7.0k782.0k987.0k249.0k348.0k273.0k

Cash From Operating Activities

(4.2m)(2.0m)(1.3m)(1.6m)(48.0k)(558.0k)(1.1m)(288.0k)(883.0k)

Purchases of PP&E

(34.0k)(13.0k)(60.0k)(89.0k)(57.0k)(149.0k)(157.0k)(58.0k)(113.0k)

Cash From Investing Activities

(514.0k)(156.0k)(483.0k)(651.0k)(201.0k)(396.0k)(529.0k)(119.0k)(291.0k)

Cash From Financing Activities

5.9m935.0k2.0m2.7m392.0k1.1m2.5m(53.0k)694.0k

Interest Paid

2.0k1.0k2.0k3.0k

International Stem Cell Corporation Ratios

USDY, 2019

Financial Leverage

-7.2 x